Important ongoing phase III studies that might change the treatment landscape of NSCLC are KEYNOTE-024 comparing pembrolizumab to chemotherapy in PD-L1 + NSCLC, and CheckMate 026 with nivolumab, both in treatment-naïve advanced NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.